镰状细胞病疼痛危象患儿阿片类药物给药及时性指南依从性的多年横断面研究
该研究为多年横断面分析,纳入2016年1月1日至2018年12月31日期间7个儿科急诊中心(儿科急诊应用研究网络内)就诊的镰状细胞病(SCD)疼痛危象患儿,共4578次就诊。纳入标准为无并发症疼痛危象(ICD-9/10 SCD危象编码且接受阿片类药物),排除其他SCD并发症或体温超过38.5°C(101.3°F)的就诊。结果显示首剂阿片类中位时间为62分钟(IQR 42–93),首剂至第二剂中位间隔60分钟(IQR 39–93);总体48%(95%CI 47%–50%)的就诊首剂符合指南,3538次接受第二剂就诊中仅15%(95%CI 14%–16%)符合。各中心依从性差异显著(首剂22%–70%,第二剂间隔2%–36%,均P<.001),且各年度间无改善(P>.05)。结论认为指南依从性差,亟需传播与实施研究/质量改进。
要点
- 首剂阿片类中位时间62分钟(IQR 42–93),仅48%(95%CI 47%–50%)的就诊在1小时内给药,未达国家心肺血液研究所指南推荐。
- 首剂至第二剂中位间隔60分钟(IQR 39–93),仅15%(95%CI 14%–16%)符合每30分钟给药直至疼痛控制的指南推荐。
- 各中心依从性差异大:首剂依从率22%–70%,第二剂间隔依从率2%–36%(均P<.001)。
- 2016–2018各年度间首剂及时性或给药间隔均无改善(P>.05)。
- 作者认为亟需传播与实施研究/质量改进以改善急诊SCD疼痛危象的及时治疗。
适用人群与场景
- 2016年1月1日至2018年12月31日期间,7个儿科急诊中心(儿科急诊应用研究网络内)就诊的镰状细胞病(SCD)疼痛危象患儿。
- 纳入无并发症疼痛危象就诊,定义为ICD-9/ICD-10 SCD危象编码且接受阿片类药物。
- 排除其他SCD并发症或体温超过38.5°C(101.3°F)的就诊。
诊断标准与关键阈值
- 无并发症疼痛危象定义:ICD-9/ICD-10 SCD危象编码且接受阿片类药物,并排除其他SCD并发症或体温超过38.5°C(101.3°F)。
- 指南依从性定义:首剂阿片类在到达后1小时内给药;后续每30分钟给药直至疼痛控制(依据国家心肺血液研究所循证指南)。
研究设计与关键结果
- 研究类型:多年横断面分析;样本量4578次就诊;7个儿科急诊中心(儿科急诊应用研究网络内);人群为SCD疼痛危象患儿。
- 首剂阿片类中位时间62分钟(IQR 42–93分钟);首剂至第二剂中位间隔60分钟(IQR 39–93分钟)。
- 总体48%(95%CI 47%–50%)的就诊首剂符合指南;3538次接受第二剂就诊中15%(95%CI 14%–16%)符合指南。
- 各中心首剂依从率范围22%–70%,第二剂间隔依从率范围2%–36%(均P<.001)。
- 各年度间首剂及时性或给药间隔无变化(P>.05)。
证据类型、等级与局限
- 证据类型:多年横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,传播与实施研究/质量改进对改善各急诊SCD疼痛危象患儿的及时治疗至关重要。
指南或共识出处
- 国家心肺血液研究所镰状细胞病疼痛危象阿片类药物给药及时性循证指南(建议到达后1小时内给予首剂阿片类,随后每30分钟给药直至疼痛控制)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: The National Heart, Lung, and Blood Institute evidence-based guidelines for timeliness of opioid administration for sickle cell disease (SCD) pain crises recommend an initial opioid within 1 hour of arrival, with subsequent dosing every 30 minutes until pain is controlled. No multisite studies have evaluated guideline adherence, to our knowledge. Our objective was to determine guideline adherence across a multicenter network.
METHODS: We conducted a multiyear cross-sectional analysis of children with SCD who presented between January 1, 2016, and December 31, 2018, to 7 emergency departments (EDs) within the Pediatric Emergency Care Applied Research Network. Visits for uncomplicated pain crisis were included, defined with an International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 code for SCD crisis and receipt of an opioid, excluding visits with other SCD complications or temperature exceeding 38.5°C (101.3°F). Times were extracted from the electronic record. Guideline adherence was assessed across sites and calendar years.
RESULTS: A total of 4,578 visits were included. The median time to first opioid receipt was 62 minutes (interquartile range 42 to 93 minutes); between the first and second opioid receipt, 60 minutes (interquartile range 39 to 93 minutes). Overall, 48% of visits (95% confidence interval 47% to 50%) were guideline adherent for first opioid. Of 3,538 visits with a second opioid, 15% (95% confidence interval 14% to 16%) were guideline adherent. Site variation in adherence existed for time to first opioid (range 22% to 70%) and time between first and second opioid (range 2% to 36%; both P<.001). There was no change in timeliness to first dose or time between doses across years (P>.05 for both).
CONCLUSION: Guideline adherence for timeliness of SCD treatment is poor, with half of visits adherent for time to first opioid and one seventh adherent for second dose. Dissemination and implementation research/quality improvement efforts are critical to improve care across EDs.
参考来源
- Brousseau DC, Alpern ER, Chamberlain JM, et al. A Multiyear Cross-sectional Study of Guideline Adherence for the Timeliness of Opioid Administration in Children With Sickle Cell Pain Crisis. Ann Emerg Med. 2020. PMID: 32928464. doi:10.1016/j.annemergmed.2020.08.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。